4,5,6,7-tetrahydrofuro<3,2-c>pyridine-4-methanol | 129823-17-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4,5,6,7-tetrahydrofuro<3,2-c>pyridine-4-methanol
• 英文别名: 4,5,6,7-Tetrahydrofuro[3,2-c]pyridine-4-methanol；4,5,6,7-tetrahydrofuro[3,2-c]pyridin-4-ylmethanol
• CAS: 129823-17-2
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: CWVREJCLIAHUPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  45.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,5,6,7-tetrahydrofuro<3,2-c>pyridine-4-methanol 在 盐酸 、 3 A molecular sieve 、 sodium cyanoborohydride 、 N,N'-羰基二咪唑 作用下， 反应 20.5h， 生成 5-[(3,4-Dichlorophenyl)acetyl]-4,5,6,7-tetrahydro-4[(1,2,3,6-tetrahydro-1-pyridinyl)methyl]furo[3,2-c]pyridine
  参考文献：
  名称：

  4-[(Alkylamino)methyl]furo[3,2-c]pyridines: A New Series of Selective .kappa.-Receptor Agonists

  摘要：

  The synthesis of 5-(arylacetyl)-4-[(alkylamino)methyl]furo[3,2-c]pyridines (16-23, 26, 27) and their activities as kappa-opioid receptor agonists are described. kappa-Agonist potency was particularly sensitive to the nature of the basic moiety. In particular, in the rabbit vas deferens (kappa-specific tissue), the 3-pyrrolidinol analogue 17 (IC50 = 2.7 nM) was found to be approximately 5-fold more potent than the corresponding pyrrolidine analogue 16 (IC50 15 nM). In the rat and hamster vasa deferentia (mu-specific and delta-specific tissues, respectively), 17 showed only weak antagonist activity (PKB > 5.5), underlining its selectivity for the kappa-opioid receptor. The major activity for 17 is resident in the 4S,3'S-isomer 26 (rabbit vas deferens IC50 = 1.1 nM). Compound 26 displays excellent antinociceptive activity, as determined in the mouse acetylcholine-induced abdominal constriction test (ED(50) = 0.001 mg/kg, sc).

  DOI：

  10.1021/jm00040a004
• 作为产物：
  描述：

  2-氨基乙基呋喃 在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 4,5,6,7-tetrahydrofuro<3,2-c>pyridine-4-methanol
  参考文献：
  名称：

  4-[(Alkylamino)methyl]furo[3,2-c]pyridines: A New Series of Selective .kappa.-Receptor Agonists

  摘要：

  The synthesis of 5-(arylacetyl)-4-[(alkylamino)methyl]furo[3,2-c]pyridines (16-23, 26, 27) and their activities as kappa-opioid receptor agonists are described. kappa-Agonist potency was particularly sensitive to the nature of the basic moiety. In particular, in the rabbit vas deferens (kappa-specific tissue), the 3-pyrrolidinol analogue 17 (IC50 = 2.7 nM) was found to be approximately 5-fold more potent than the corresponding pyrrolidine analogue 16 (IC50 15 nM). In the rat and hamster vasa deferentia (mu-specific and delta-specific tissues, respectively), 17 showed only weak antagonist activity (PKB > 5.5), underlining its selectivity for the kappa-opioid receptor. The major activity for 17 is resident in the 4S,3'S-isomer 26 (rabbit vas deferens IC50 = 1.1 nM). Compound 26 displays excellent antinociceptive activity, as determined in the mouse acetylcholine-induced abdominal constriction test (ED(50) = 0.001 mg/kg, sc).

  DOI：

  10.1021/jm00040a004

文献信息

• Pharmaceutically useful furo[3,2-c]pyridines
  申请人：Glaxo Group Limited

  公开号：US05109008A1

  公开（公告）日：1992-04-28

  Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents hydrogen, unsubstituted or substituted C.sub.1-6 alkyl, halogen, --COR.sub.4 or --CO.sub.2 R.sub.4 (where R.sub.4 represents hydrogen or unsubstituted or substituted C.sub.1-6 alkyl); R.sub.2 and R.sub.3 are the same or different and are C.sub.1-6 alkyl or C.sub.3-6 alkenyl; or --NR.sub.2 R.sub.3 forms a 5-membered (optionally containing an oxygen atom adjacent to the nitrogen) or a 6-membered ring, which ring optionally contains one unit of unsaturation and which is unsubstituted or substituted by hydroxy, C.sub.1-6 acyloxy, oxo, optionally substituted methylidene, --COR.sub.5 (where R.sub.5 represents C.sub.1-6 alkyl, OR.sub.6 or --NHR.sub.6, and R.sub.6 represents hydrogen, C.sub.1-6 alkyl, aryl or ar(C.sub.1-6)alkyl) or said ring is substituted by .dbd.NOR.sub.7 (where R.sub.7 represents C.sub.1-6 alkyl); Z represents --O-- or --S--; X represents a direct bond, --CH.sub.2 -- or --CH.sub.2 O--; Ar represents a substituted phenyl moiety; and pharmaceutically acceptable salts thereof. The compounds are indicated as useful in the treatment of pain and cerebral ischaemia. Processes and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.

  公开了式（I）的化合物 其中，R.sub.1代表氢，未取代或取代的C.sub.1-6烷基，卤素，-COR.sub.4或-CO.sub.2R.sub.4（其中R.sub.4代表氢或未取代或取代的C.sub.1-6烷基）; R.sub.2和R.sub.3相同或不同，是C.sub.1-6烷基或C.sub.3-6烯基; 或-NR.sub.2R.sub.3形成一个5-成员环（可选地包含与氮相邻的氧原子）或6-成员环，该环可选地含有一个不饱和单元，未取代或取代的羟基，C.sub.1-6酰氧基，氧代，可选地取代的甲基亚甲基，-COR.sub.5（其中R.sub.5代表C.sub.1-6烷基，OR.sub.6或-NHR.sub.6，R.sub.6代表氢，C.sub.1-6烷基，芳基或芳基（C.sub.1-6）烷基）或所述环被.dbd.NOR.sub.7（其中R.sub.7代表C.sub.1-6烷基）取代; Z代表-O-或-S-; X代表直接键，-CH.sub.2-或-CH.sub.2O-; Ar代表取代的苯基基团;以及其药物可接受的盐。这些化合物被指示为治疗疼痛和脑缺血的有用药物。还公开了它们的制备过程和中间体以及含有它们的制药组合物。
• Naylor Alan, Judd Duncan B., Scopes David I. C., Hayes Ann G., Birch Phil+, J. Med. Chem, 37 (1994) N 14, S 2138-2144
  作者：Naylor Alan, Judd Duncan B., Scopes David I. C., Hayes Ann G., Birch Phil+

  DOI：——

  日期：——
• US5109008A
  申请人：——

  公开号：US5109008A

  公开（公告）日：1992-04-28